Thomas Jaki
Thomas Jaki
Programme Leader at MRC Biostatistics Unit and Professor of Statistics at Lancaster University
Verified email at - Homepage
Cited by
Cited by
A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19
B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, ...
New England Journal of Medicine, 2020
Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report
P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, N Staplin, ...
The New England Journal of Medicine 383, 693-704, 2021
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu, L Gao, Z Cheng, Q Lu, ...
The Lancet 395 (10236), 1569-1578, 2020
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
P Horby, M Mafham, L Linsell, JL Bell, N Staplin, JR Emberson, M Wiselka, ...
The New England journal of medicine, 2020
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 1-15, 2018
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ...
The Lancet 396 (10259), 1345-1352, 2020
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ...
The Lancet 397 (10285), 1637-1645, 2021
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
D Magirr, T Jaki, J Whitehead
Biometrika 99 (2), 494-501, 2012
Probabilistic relabelling strategies for the label switching problem in Bayesian mixture models
M Sperrin, T Jaki, E Wit
Statistics and Computing 20 (3), 357-366, 2010
Assessing differential effects: Applying regression mixture models to identify variations in the influence of family resources on academic achievement.
ML Van Horn, T Jaki, K Masyn, SL Ramey, JA Smith, S Antaramian
Developmental psychology 45 (5), 1298, 2009
Optimal design of multi‐arm multi‐stage trials
J Wason, T Jaki
Statistics in Medicine 31 (30), 4269-4279, 2012
Some recommendations for multi-arm multi-stage trials
J Wason, D Magirr, M Law, T Jaki
Statistical methods in medical research 25 (2), 716-727, 2016
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
PW Horby, L Estcourt, L Peto, JR Emberson, N Staplin, E Spata, ...
Lancet 397 (10289), 2049-2059, 2021
Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report
P Horby, WS Lim, J Emberson, M Mafham, J Bell, L Linsell, N Staplin, ...
Differential effects of parental controls on adolescent substance use: For whom is the family most important?
AA Fagan, ML Van Horn, JD Hawkins, T Jaki
Journal of quantitative criminology 29 (3), 347-368, 2013
A review of statistical updating methods for clinical prediction models
TL Su, T Jaki, GL Hickey, I Buchan, M Sperrin
Statistical methods in medical research 27 (1), 185-197, 2018
Estimation of pharmacokinetic parameters with the R package PK
T Jaki, MJ Wolfsegger
Pharmaceutical Statistics, 2011
Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks
N Dean, PS Gsell, R Brookmeyer, F Crawford, C Donnelly, S Ellenberg, ...
The New England Journal of Medicine 382 (14), 1366-1369, 2020
A Bayesian adaptive design for clinical trials in rare diseases
SF Williamson, P Jacko, SS Villar, T Jaki
Computational Statistics & Data Analysis 113, 136-153, 2017
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo …
Y Wang, F Zhou, D Zhang, J Zhao, R Du, Y Hu, Z Cheng, L Gao, Y Jin, ...
Trials 21, 1-11, 2020
The system can't perform the operation now. Try again later.
Articles 1–20